Perrigo receives FDA approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)

Perrigo Company has announced that it has received final approval from the U.S. Food and Drug Administration to market Sulfacetamide Sodium Topical Suspension, 10% (Lotion).

The product has been determined to be therapeutically equivalent (AB) to Sanofi-Aventis' Klaron(R) (Sodium Sulfacetamide) Lotion, 10%, which is indicated for the topical treatment of acne. Klaron(R) Lotion had sales of approximately $15 million for the 12 months ended January 2009, as measured by Wolters Kluwer Health.

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This approval is another example of our commitment to invest in and bring new products to market. It further demonstrates our strategy to deliver quality affordable healthcare both behind and over the counter."